Shanghai, China · Founded 2018 · In IPO Registration
Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. Tyligand Bioscience is based in Shanghai, China and was founded in 2018. Its last reported valuation was $222 million in Jan 2026. It has raised $111 million.
Last reported valuation
$222.2M
Oct 2026
Priced at
—
Total raised
$110.6M
Last round
—
Team — not yet on record
No current team members for Tyligand Bioscience are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Tyligand Bioscience with a free account
·The complete investor list: 14 names
·Watch Tyligand Bioscience: the Monday email on marks, rounds and moves
